logo

Concert Pharmaceuticals, Inc. (CNCE)



Trade CNCE now with
  Date
  Headline
5/30/2017 7:07:36 AM Concert Pharmaceuticals CFO Ryan Daws To Be Leaving Company In Early June 2017
5/24/2017 10:02:22 AM Concert Pharma Shareholders Approve CTP-656 Asset Purchase Agreement With Vertex Pharma
5/22/2017 7:01:26 AM Concert Pharma Receives Second Request From FTC In Connection With Pending Acquisition Of CTP-656 And Other Assets
5/17/2017 7:32:08 AM Concert Pharmaceuticals Announces Clinical Hold On CTP-543 Phase 2a Trial
5/2/2017 7:14:01 AM Concert Pharma Q1 Loss Per Share $0.60 Vs Loss $0.63 Last Year
5/2/2017 6:33:18 AM Concert Pharma Begins CTP-543 Phase 2 Trial In Alopecia Areata
3/6/2017 7:17:33 AM Concert Pharma Q4 Loss/shr $0.54 Vs. EPS $0.03 Prior Year
3/6/2017 7:01:20 AM Vertex To Buy CTP-656 From Concert Pharmaceuticals For Treatment Of Cystic Fibrosis
1/20/2017 8:36:49 AM Concert Pharma Gets FDA Orphan Drug Designation For CTP-656 For The Treatment Of Cystic Fibrosis